-

Abstract

Stevens-Johnson Syndrome is an acute, usually self-limiting disease of the skin and mucous membranes. Vesiculobullous skin lesions with two or more mucosal area are usually affected in this disease. Especially drugs, various infectious agents, malignancy, collagen tissue diseases are common etiological factors of Stevens-Johnson Syndrome. Rate of the patients’ mortality with SJS is %3-%18. There is no specific treatment. Early withdrawal of implicated agent and supportive therapy as applied to the first treatment method. Corticosteroids, intravenous immunoglobulin (IVIG), immunosuppressive drugs, hemodialysis, plasmapheresis, hyperbaric oxygen is the other treatment options. In this study, we aimed to discuss the treatment approach of Stevens-Johnson Syndrome on a case that developed Stevens-Johnson Syndrome following to use of drug for upper respiratory tract infection

Keywords

• -

Steven Johnson Sendromu: Olgu Sunumu

Abstract

Stevens-Johnson Sendromu, akut başlangıçlı, genellikle kendini sınırlayan, vezikülobüllöz, deri lezyonlarının yanı sıra en az iki mukozal alanın tutulduğu bir hastalıktır. Etyolojide özellikle ilaçlar, çeşitli enfeksiyon ajanlar, malignite, kollagen doku hastalıkları rol oynamaktadır. Stevens-Johnson Sendromu olguların % 3-18’inde ölüme yol açmaktadır. Spesifik tedavisi yoktur. Sebep olan ajandan uzaklaşılması ve destek tedavisi ilk olarak uygulanacak tedavi yöntemidir. immunsupresif ilaçlar, hemodiyaliz, plazmaferez, hiperbarik oksijen diger tedavi secenekleridir. Bu çalışmamızda üst solunum yolu enfeksiyonu nedeniyle ilaç kullanımını takiben Stevens-Johnson Sendromu gelişen olguya tedavi yaklaşımını tartışmayı amaçladık

Keywords

• Steven Johnson Sendromu, Tedavi, İntravenöz İmmünglobülin

References

1. Prins C, Vittorio C, Padilla RS, et al. Effect of high-dose intravenous immunoglobulin therapy in Stevens- Johnson syndrome: a retrospective, multicenter study. Dermatology 2003;207(1):96-9.
2. Dalli RL, Kumar R, Kennedy P, Maitz P, Lee S, Johnson R. Toxic epidermal necrolysis/Stevens- Johnson syndrome: current trends in management. ANZ J Surg 2007;77(8):671-6.
3. Viard I, Wehrli P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282(5388):490-3.
4. Akman A, Alpsoy E: Eritema Multiforme, Steven-Johnson Sendromu ve Toksik Epidermal Nekroliz (Lyell Sendromu). Türkiye Klinikleri J Surg Med Sci 2006; 2(3):6-15.
5. Rappersberger K, Foedinger D. Treatment of erythema multiforme, Stevens - Johnson syndrome, and toxic epidermal necrolysis. Dermatol Therapy 2002;15(4):397-408.
6. Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens- Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000; 136(3):323-7.
7. Forman R, Koren G, Shear NH. Erythema Multiforme, Stevens - Johnson syndrome and Toxic Epidermal Necrolysis in children. Drug Safety 2002;25(13)965-72.
8. Agrawal A, Bramble MG, Shehade S, Dean J. Oesaphageal stricturing secondary to adult Stevens-Johnson Syndrome: similarities in presentation and management of corrosive injury. Endoscopy 2003;35(5):454-7.

9. Roujeau JC, Kelly JP, Naldi L et al. Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333(24):1600–7.
10. Sharma VK, Sethuraman G, Minz A. Stevens Johnson syndrome, toxic epidermal necrolysis and SJS-TEN overlap: a retrospective study of causative drugs and clinical outcome. Indian J Dermatol Venereol Leprol 2008;74(3):238-40.
11. Hazin R, Ibrahimi OA, Hazini MI, Kimyai-Asadi A. Stevens-Johnson syndrome: Pathogenesis, diagnosis, and management Annals of Medicine 2008;40(2):129-138.